围手术期全身治疗对比单纯手术用于可切除结直肠腹膜转移(CAIRO6)
CAIRO6是一项随机、开放标签、3期试验,在荷兰9个和比利时1个三级中心开展,纳入358例可切除结直肠腹膜仅有转移的患者,随机接受围手术期全身治疗联合CRS-HIPEC或直接CRS-HIPEC。结论为围手术期全身治疗不能推荐用于所有可切除结直肠腹膜仅有转移的患者。
要点
- 围手术期全身治疗未显著改善可切除结直肠腹膜仅有转移患者的总生存。
- 围手术期治疗组术后90天主要并发症发生率36%,高于单纯手术组的26%。
- 围手术期全身治疗相关3-4级毒性发生率为57%,包括高血压、腹泻、中性粒细胞减少和血栓栓塞事件。
核心结论
- 围手术期全身治疗不能推荐用于所有可切除结直肠腹膜仅有转移的患者。
研究设计与样本
- 随机、开放标签、3期试验,在荷兰9个和比利时1个三级中心开展,共纳入358例患者,随机1:1分配至围手术期全身治疗联合CRS-HIPEC组(n=180)或单纯CRS-HIPEC组(n=178)。
- 改良意向治疗人群共351例(围手术期治疗组173例,单纯手术组178例),中位随访41个月(IQR 21-62)。
主要发现
- 在292例接受宏观完全或近完全CRS-HIPEC的患者中,围手术期治疗组90天主要术后并发症发生率为36%(49/138),单纯手术组为26%(40/154)。
- 围手术期治疗组90天术后死亡率1%(2例),单纯手术组1%(1例)。
- 开始围手术期全身治疗的患者中,57%(92/161)发生主要全身治疗相关毒性(CTCAE 3-5级)。
关键数值与推荐
- 围手术期全身治疗方案由研究者选择,包括CAPOX、FOLFOX或FOLFIRI联合或不联合贝伐珠单抗。
- 主要术后并发症定义为Clavien-Dindo 3-5级,评估至术后90天。
- 主要全身治疗相关毒性定义为CTCAE 3-5级,评估至末次给药后30天。
临床怎么用
- 对于可切除结直肠腹膜仅有转移的患者,不应常规推荐围手术期全身治疗。
- 临床决策需权衡围手术期全身治疗带来的毒性风险与未显著的总生存获益。
局限性
- 改良意向治疗人群排除了治疗前撤回知情同意或违反主要入选标准的患者。
- 围手术期全身治疗方案由研究者选择,异质性可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data are sparse on the value of perioperative systemic therapy in patients with resectable colorectal peritoneal-only metastases. This trial aimed to compare the efficacy of perioperative systemic therapy versus surgery alone in this population. METHODS: This randomised, open-label, phase 3 trial was done at all nine Dutch tertiary centres and one Belgian tertiary centre. Eligible patients were aged 18 years or older with a WHO performance status of 0 or 1 and pathologically proven resectable peritoneal-only metastases of a colorectal adenocarcinoma who did not receive systemic therapy for at least 6 months. Enrolled patients were randomly assigned (1:1) to perioperative systemic therapy and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC; perioperative systemic therapy group) or upfront CRS-HIPEC alone (surgery alone group) using a web-based system with minimisation stratified by previous systemic therapy, synchronous or metachronous peritoneal metastases, peritoneal cancer index 0-10 or 11-20, and mitomycin C-based or oxaliplatin-based HIPEC. At investigator's choice, perioperative systemic therapy comprised either four 3-week neoadjuvant and adjuvant cycles of CAPOX (intravenous oxaliplatin 130 mg/m2 followed by oral capecitabine 1000 mg/m2 twice per day on days 1-14), six 2-week neoadjuvant and adjuvant cycles of FOLFOX (intravenous oxaliplatin 85 mg/m2 with intravenous leucovorin 400 mg/m2, followed by bolus intravenous 5-fluorouracil 400 mg/m2, and continuous intravenous 5-fluorouracil 2400 mg/m2 for 48 h), or six 2-week neoadjuvant cycles of FOLFIRI (intravenous irinotecan 180 mg/m2 with intravenous leucovorin 400 mg/m2, followed by bolus intravenous 5-fluorouracil 400 mg/m2, and continuous intravenous 5-fluorouracil 2400 mg/m2 for 48 h) followed by either four 3-week adjuvant cycles of oral capecitabine (1000 mg/m2 twice per day on days 1-14) or six 2-week adjuvant cycles of 5-fluorouracil and leucovorin (intravenous leucovorin 400 mg/m2, followed by bolus intravenous 5-fluorouracil 400 mg/m2, and continuous intravenous 5-fluorouracil 2400 mg/m2 for 48 h). Intravenous bevacizumab was added to the first three neoadjuvant cycles of CAPOX (7·5 mg/kg) or the first four neoadjuvant cycles of FOLFOX or FOLFIRI (5 mg/kg). The primary outcome was overall survival assessed in a prespecified modified intention-to-treat population, excluding patients who withdrew consent before treatment or violated major eligibility criteria. Major postoperative morbidity was defined as Clavien-Dindo grade 3-5 and assessed up to 90 days postoperatively. Major systemic therapy-related toxicity was defined as Common Terminology Criteria for Adverse Events (CTCAE) grade 3-5 and assessed up to 30 days after its last administration. The Dutch patient organisation for colorectal cancer was involved in the trial design. The trial is registered with Clinicaltrials.gov (NCT02758951) and is active but not recruiting. FINDINGS: Between June 15, 2017, and April 29, 2024, 1922 patients were screened for eligibility. Of these, 358 patients were enrolled and randomly assigned to perioperative systemic therapy (n=180) or surgery alone (n=178). 351 patients were included in the modified intention-to-treat population (173 patients randomly assigned to perioperative systemic therapy and 178 patients to surgery alone; 181 [52%] male and 170 [48%] female). After a median follow-up of 41 months (IQR 21-62), median overall survival was 44 months (95% CI 30-54) in the perioperative systemic therapy group versus 39 months (95% CI 31-46) in the surgery alone group (hazard ratio [HR] 0·85, 95% CI 0·62-1·15; p=0·28). In 292 patients who underwent macroscopic complete or near complete CRS-HIPEC, major 90-day postoperative morbidity occurred in 49 (36%) of 138 patients in the perioperative systemic therapy group and in 40 (26%) of 154 patients in the surgery alone group. The most common Clavien-Dindo grade 3-4 postoperative adverse events were intra-abdominal abscess (16 [12%] of 138 patients in the perioperative systemic therapy group vs 16 [10%] of 154 patients in the surgery alone group), anastomotic leakage (12 [9%] vs six [4%]), and fascia dehiscence (13 [9%] vs six [4%]). 90-day postoperative mortality occurred in two (1%) patients in the perioperative systemic therapy group (anastomotic leakage and cerebrovascular accident) and in one (1%) patient in the surgery alone group (anastomotic leakage). Major systemic therapy-related toxicity occurred in 92 (57%) of 161 patients who started perioperative systemic therapy. The most common CTCAE grade 3-4 systemic therapy-related adverse events were hypertension (13 [8%] patients), diarrhoea (12 [7%] patients), neutropenia (11 [7%] patients), and thromboembolic events (ten [6%] patients). Systemic therapy-related death occurred in one (1%) patient (hyperglycaemia). INTERPRETATION: Perioperative systemic therapy cannot be recommended in all patients with resectable colorectal peritoneal-only metastases. FUNDING: Dutch Cancer Society, F Hoffman-La Roche.
引用
- Rovers KP, Bakkers C, van den Heuvel TBM, et al. Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial. Lancet Oncol. 2026. PMID: 42372745. doi:10.1016/S1470-2045(26)00085-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。